Joe Palca | KUNR

Joe Palca

Conventional wisdom says that if you're vaccinated and you get a breakthrough infection with the coronavirus, you can transmit that infection to someone else and make that person sick.

But new evidence suggests that even though that may happen on occasion, breakthrough infections might not represent the threat to others that scientists originally thought.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

AUDIE CORNISH, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Pfizer's request to offer a third dose of its COVID-19 vaccine to all Americans 16 or older ran into strong headwinds today.

(SOUNDBITE OF ARCHIVED RECORDING)

Copyright 2021 NPR. To see more, visit https://www.npr.org.

NOEL KING, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

When Dr. Anthony Fauci spoke recently at a White House briefing about the need for COVID-19 booster shots, buried in his slideshow of charts and data points was a little-noticed scientific paper that offers evidence for a reliable way to predict how much protection a COVID-19 vaccine offers.

The government says people who were vaccinated against COVID-19 eight months ago will need a booster.

That decision is based in part on blood tests that show antibody levels in vaccinated people decline over time.

Some of those tests were done at the University of Texas Medical Branch in Galveston, Texas.

Why there?

With the U.S. in the grips of a frightening surge of coronavirus cases, many parents are understandably eager to know when the COVID-19 vaccine will finally be available for children under 12.

This age group accounts for about 50 million Americans and currently none of them qualify for a shot. But scientists are racing to figure out how one of the COVID-19 vaccines currently available for adults could be given to this age group.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

Copyright 2021 NPR. To see more, visit https://www.npr.org.

ARI SHAPIRO, HOST:

The first results from a large efficacy study of a new kind of COVID-19 vaccine are now out, and they are good. Very good.

According to Novavax, the vaccine's manufacturer, it had a 100% efficacy against the original strain of the coronavirus and 93% efficacy against more worrisome variants that have subsequently appeared.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

SARAH MCCAMMON, HOST:

The emergence of new and more infectious variants of the coronavirus has raised a troubling question: Will the current crop of COVID-19 vaccine prevent these variants from causing disease?

A study out Wednesday in the journal Nature suggests the answer is yes.

Updated June 7, 2021 at 2:08 PM ET

Jupiter's moon Ganymede had a visitor from Earth on Monday. NASA's Juno spacecraft zoomed by in the afternoon, just 645 miles above the surface of the solar system's largest moon.

It's the first time a probe has made a close-up visit to Ganymede since the Galileo mission flew by in 2000.

A new kind of COVID-19 vaccine could be available as soon as this summer.

It's what's known as a protein subunit vaccine. It works somewhat differently from the current crop of vaccines authorized for use in the U.S. but is based on a well-understood technology and doesn't require special refrigeration.

It's the rare individual who actually looks forward to getting jabbed with a needle, even if what's in the needle can protect them from a serious disease such as COVID-19.

But several teams around the world are working on a way to inject a vaccine without the ouch. The trick is to make the needles small. Really small. So small they don't interact with the nerve endings that signal pain.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

Pages